학술논문
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Document Type
Article
Author
Ahn, JB; Asselah, J; Badarinath, S; Baijal, S; Begbie, S; Berry, S; Canon, JL; Carbone, RG; Cervantes, A; Cha, YJ; Chang, K; Chaudhry, A; Chmielowska, E; Cho, SH; Chu, D; Couture, F; Cultrera, J; Cunningham, D; Van Cutsem, E; Cuyle, PJ; Davies, J; Dowden, S; Dvorkin, M; Ganju, V; Garcia, RV; Kerr, R; Kim, TY; King, K; Kortmansky, J; Kozloff, M; Lam, KO; Lee, J; Lee, AS; Lesperance, B; Luppi, G; Ma, B; Maiello, E; Mandanas, R; Marshall, J; Marx, G; Mullamitha, S; Nechaeva, M; Park, JO; Pavlakis, N; Ponce, CG; Potemski, P; Raouf, S; Reeves, J; Segal, N; Siena, S; Smolin, A; Streb, JO; Strickland, A; Szutowicz-Zielinska, E; Tabernero, JM; Tan, B; Valera, JS; Van den Eynde, M; Vergauwe, P; Vickers, M; Womack, M; Wroblewska, M; Young, R; Eng, Cathy; Kim, Tae Won; Bendell, Johanna; Argilés, Guillem; Tebbutt, Niall C; Di Bartolomeo, Maria; Falcone, Alfredo; Fakih, Marwan; Kozloff, Mark; Segal, Neil H; Sobrero, Alberto; Yan, Yibing; Chang, Ilsung; Uyei, Anne; Roberts, Louise; Ciardiello, Fortunato
Source
In The Lancet Oncology June 2019 20(6):849-861
Subject
Language
ISSN
1470-2045